Article Text
Commentary: General medicine
Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate
Statistics from Altmetric.com
Footnotes
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.